References:
1 Sandborn WJ, Su C, Sands BE, D’Haens GR, Vermeire S, Schreiber S, Danese S, Feagan BG, Reinisch W, Niezychowski W, Friedman G. Tofacitinib as induction and maintenance therapy for ulcerative colitis. New England Journal of Medicine. 2017 May 4;376(18):1723-36. DOI: 10.1056/NEJMoa1606910
2 Pfizer Inc. Xeljanz prescribing information. 2012. Retrieved from http://labeling.pfizer.com/ShowLabeling.aspx?id=959.
3 Mahadevan U, Dubinsky MC, Su C, Lawendy N, Jones TV, Marren A, Zhang H, Graham D, Clowse ME, Feldman SR, Baumgart DC. Outcomes of pregnancies with maternal/paternal exposure in the tofacitinib safety databases for ulcerative colitis. Inflammatory bowel diseases. 2018 Nov 29;24(12):2494-500. DOI: 10.1093/ibd/izy160
4 Laube R, Selinger CP, Seow CH, Christensen B, Flanagan E, Kennedy D, Mountifield R, Seeho S, Shand A, Williams AJ, Leong RW. Australian inflammatory bowel disease consensus statements for preconception, pregnancy and breast feeding. Gut. 2023 Jun 1;72(6):1040-53. DOI: 10.1136/gutjnl-2022-329304
5 Ghoreschi K, Jesson MI, Li X, Lee JL, Ghosh S, Alsup JW, Warner JD, Tanaka M, Steward-Tharp SM, Gadina M, Thomas CJ. Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550). The Journal of Immunology. 2011 Apr 1;186(7):4234-43. DOI: 10.4049/jimmunol.1003668
6 Fleischmann R, Kremer J, Cush J, Schulze-Koops H, Connell CA, Bradley JD, Gruben D, Wallenstein GV, Zwillich SH, Kanik KS. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. New England Journal of Medicine. 2012 Aug 9;367(6):495-507. DOI: 10.1056/NEJMoa1109071
7 Gladman D, Rigby W, Azevedo VF, Behrens F, Blanco R, Kaszuba A, Kudlacz E, Wang C, Menon S, Hendrikx T, Kanik KS. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. New England Journal of Medicine. 2017 Oct 19;377(16):1525-36. DOI: 10.1056/NEJMoa1615977
8 Ruperto N, Brunner HI, Synoverska O, Ting TV, Mendoza CA, Spindler A, Vyzhga Y, Marzan K, Grebenkina L, Tirosh I, Imundo L. Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. The Lancet. 2021 Nov 27;398(10315):1984-96. DOI: 10.1016/S0140-6736(21)01255-1
9 Deodhar A, Sliwinska-Stanczyk P, Xu H, Baraliakos X, Gensler LS, Fleishaker D, Wang L, Wu J, Menon S, Wang C, Dina O. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Annals of the rheumatic diseases. 2021 Aug 1;80(8):1004-13. DOI: 10.1136/annrheumdis-2020-219601
10 Clowse ME, Feldman SR, Isaacs JD, Kimball AB, Strand V, Warren RB, Xibillé D, Chen Y, Frazier D, Geier J, Proulx J. Pregnancy outcomes in the tofacitinib safety databases for rheumatoid arthritis and psoriasis. Drug safety. 2016 Aug;39:755-62. DOI: 10.1007/s40264-016-0431-z
11 Levy RA, de Jesús GR, de Jesús NR, Klumb EM. Critical review of the current recommendations for the treatment of systemic inflammatory rheumatic diseases during pregnancy and lactation. Autoimmunity reviews. 2016 Oct 1;15(10):955-63. DOI: 10.1016/j.autrev.2016.07.014
12 Skorpen CG, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, Da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Annals of the rheumatic diseases. 2016 Feb 17:annrheumdis-2015. DOI: 10.1136/annrheumdis-2015-208840
13 Torres J, Chaparro M, Julsgaard M, Katsanos K, Zelinkova Z, Agrawal M, Ardizzone S, Campmans-Kuijpers M, Dragoni G, Ferrante M, Fiorino G. European Crohn’s and colitis guidelines on sexuality, fertility, pregnancy, and lactation. Journal of Crohn’s and Colitis. 2023 Jan 1;17(1):1-27. DOI: 10.1093/ecco-jcc/jjac115
14 Irving PM, Leung Y, Dubinsky MC. guide to tofacitinib dosing in patients with ulcerative colitis. Alimentary Pharmacology & Therapeutics. 2022 Oct;56(7):1131-45. DOI: 10.1111/apt.17185
15 Julsgaard M, Mahadevan U, Vestergaard T, Mols R, Ferrante M, Augustijns P. Tofacitinib concentrations in plasma and breastmilk of a lactating woman with ulcerative colitis. The Lancet Gastroenterology & Hepatology. 2023 May 31. DOI: 10.1016/S2468-1253(23)00158-9
16 Fernández‐Sánchez M, Ribes‐Artero H, Romá‐Sánchez E, Gómez‐Portero MR, Guerrero‐Hurtado E, García‐Pellicer J, Poveda‐Andrés JL. Fetal exposure to tofacitinib during the first trimester: A healthy newborn case report. Birth Defects Research. 2021 Oct 15;113(17):1275-9. DOI: 10.1002/bdr2.1942
17 Chaparro M, Donday MG, Abad-Santos F, Martin de Carpi FJ, Maciá-Martínez MÁ, Montero D, Acosta D, Brenes Y, Gisbert JP. The safety of drugs for inflammatory bowel disease during pregnancy and breastfeeding: the DUMBO registry study protocol of GETECCU. Therapeutic Advances in Gastroenterology. 2021 Jun;14:17562848211018097. DOI: 10.1177/17562848211018097
Figure 1: The timeline of events during pregnancy in our patient with ulcerative colitis who was in remission on tofacitinib 10mg twice daily and found to be pregnant at six weeks of gestation.